News & Updates
Filter by Specialty:
Show Multimedia Only

Inactive disease a viable target in tofacitinib-treated patients with JIA
16 Sep 2025
byStephen Padilla
Treatment with tofacitinib improves the rates of Juvenile Arthritis Disease Activity Score (JADAS) in 10 joints (JADAS10)-clinically inactive disease (CID) and American College of Rheumatology (ACR)-CID in patients with juvenile idiopathic arthritis (JIA), with improvements sustained over time, a study has shown. Additionally, a few patients have achieved JADAS10 remission.